Modality
Fusion Protein
MOA
CAR-T BCMA
Target
PRMT5
Pathway
Checkpoint
WMWet AMD
Development Pipeline
Preclinical
~Mar 2018
→ ~Jun 2019
Phase 1
~Sep 2019
→ ~Dec 2020
Phase 2
~Mar 2021
→ ~Jun 2022
Phase 3
~Sep 2022
→ ~Dec 2023
NDA/BLA
Mar 2024
→ Aug 2026
NDA/BLACurrent
NCT06890104
1,759 pts·Wet AMD
2025-04→2026-08·Not yet recruiting
NCT07627218
2,789 pts·Wet AMD
2024-03→2025-12·Recruiting
4,548 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-12-283mo agoPh3 Readout· Wet AMD
2026-08-074mo awayPh3 Readout· Wet AMD
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3
NDA/BLA
Recruit…
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2025-12-28 · 3mo ago
Wet AMD
Ph3 Readout
2026-08-07 · 4mo away
Wet AMD
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06890104 | NDA/BLA | Wet AMD | Not yet recr... | 1759 | PFS |
| NCT07627218 | NDA/BLA | Wet AMD | Recruiting | 2789 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C |